Albany, New York, May 23, 2018: A new research study titled, “Global Market Study on Male Hypogonadism: North America to Remain Largest Market for Male Hypogonadism during 2017 – 2026” has been added to the research repository of Market Research Reports Search Engine (MRRSE). According to the research study, the global male hypogonadism market is likely to surpass US$ 3.3 Bn by the end of 2026.
According to the report, increase in the prevalence of male hypogonadism cases, and its other health impacts such as cardiovascular diseases and osteoporosis are among the key factors driving the growth of the market. Healthcare providers around the globe are focusing on developing highly effective medicines that can effectively treat the condition. The favorable support from research organizations and governments is also providing an impetus to growth. These factors are likely to provide an impetus to the growth of the male hypogonadism market during the assessment period.
According to the report, advances in testosterone replacement therapy (TST) have led to a reduction in the number of male hypogonadism cases globally. Growing awareness among both patients and healthcare providers about the effectiveness of TST is likely to provide an impetus to the growth of the market during the assessment period.
The research study offers in-depth, segment-wise analysis on the growth of the male hypogonadism market. According to the report, North America will continue to be one of the largest markets for male hypogonadism globally. In addition to being the largest market, North America is also likely to grow at the highest CAGR during the assessment period.
In addition to North America, Europe and Asia Pacific excluding Japan (APEJ) are the other key markets for male hypogonadism globally. The market in APEJ is likely to grow at a higher CAGR as compared to Europe. The research report also offers forecast and analysis on the basis of drug type. The key segments on the basis of drug type include topical gels, injectables, and transdermal patches. Among these, demand for topical gels continues to be the highest, and this segment is likely to account for a majority share of the market.
On the basis of disease type, the key segments in the market include Klinefelter’s Syndrome, Pituitary Adenomas, Kallmann Syndrome, and others. Among these, Klinefelter’s Syndrome is likely to account for a majority share of the market, whereas Pituitary Adenomas is also likely to grow at a significant CAGR.
The research study also profiles some of the key stakeholders in the male hypogonadism market. Some of the leading players in the market include Astrazeneca Plc., Bayer AG, Laboratories Genevrier, Finox Biotech, Merck & Co. Inc., Endo International Plc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company Ltd., Allergan Plc., Ferring, AbbVie Inc., and IBSA Institut Biochimque.
Browse Full Global Male Hypogonadism Market Report with TOC : https://www.mrrse.com/male-hypogonadism-market
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY – 12207